What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|July 6||Weekly Gain||My Watchlist|
|Nanosphere (Nasdaq: NSPH )||$3.91||45%||Add|
|Supernus Pharmaceuticals (Nasdaq: SUPN )||$12.05||29%||Add|
|MannKind (Nasdaq: MNKD )||$5.42||34%||Add|
|Netflix (Nasdaq: NFLX )||$81.89||20%||Add|
|Yelp (NYSE: YELP )||$25.30||11%||Add|
Nanosphere moved sharply higher after Jefferies analyst Jon Wood upgraded the company with a bullish buy rating and a $5 price target. Wood is encouraged by Nanosphere's recently approved blood infection test.
Supernus Pharmaceuticals soared 82% two weeks ago after the Food and Drug Administration tentatively approved the central nervous system treatment specialist's Trokendi drug. Momentum continued to move the stock higher last week.
Insider buying, the announcement of an upcoming conference presentation, and an analyst telling The Wall Street Journal that MannKind is a compelling acquisition target helped move the potential game changer in diabetes treatment higher.
Netflix had a double dose of good news. Citigroup's analyst issued a bullish note, pointing out that the company is trading for just 12 times the earnings of its stateside business. CEO Reed Hastings also revealed that the company served more than a billion hours of monthly video streams for the first time last month.
Yelp posted double-digit gains after reports suggested that the dining review specialist's social critiques would be incorporated into Apple's new mapping platform.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.